Skip to main content

Juvenile Idiopathic Arthritis

11
Pipeline Programs
16
Companies
11
Clinical Trials
3
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
2
0
0
1
5
3
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
764%
Small Molecule
436%
+ 5 programs with unclassified modality

On Market (3)

Approved therapies currently available

Pfizer
XELJANZ XRApproved
tofacitinib
Pfizer
oral2016
586M Part D
Pfizer
XELJANZApproved
tofacitinib
Pfizer
oral2020
280M Part D
AbbVie
HUMIRAApproved
adalimumab
AbbVie
2002
258M Part D

Competitive Landscape

11 companies ranked by most advanced pipeline stage

Pfizer
PfizerNEW YORK, NY
3 programs
1
2
1
CP-690,550Phase 31 trial
GenotropinPhase 31 trial
TofacitinibPhase 2/3Small Molecule1 trial
Active Trials
NCT01500551Completed302Est. Feb 2025
NCT02592434Completed225Est. May 2019
NCT00420251Completed50Est. Jul 2006
AbbVie
AbbVieNORTH CHICAGO, IL
2 programs
1
1
AdalimumabPhase 3Monoclonal Antibody1 trial
adalimumabN/AMonoclonal Antibody1 trial
Active Trials
NCT00783510Completed849Est. Feb 2024
NCT00775437Completed32Est. Mar 2013
Prevail Therapeutics
2 programs
2
BaricitinibPhase 3Small Molecule
BaricitinibPhase 3Small Molecule
UNION therapeutics
UNION therapeuticsDenmark - Hellerup
1 program
1
GenakumabPhase 1Monoclonal Antibody1 trial
Active Trials
NCT04337437Unknown40Est. Sep 2020
AstraZeneca
AstraZenecaCAMBRIDGE, United Kingdom
1 program
1
naproxenPhase 11 trial
Active Trials
NCT01358383Completed28Est. Jun 2011
Roche
RocheSTAVANGER NORWAY, Norway
2 programs
TocilizumabPHASE_1Monoclonal Antibody1 trial
TocilizumabPHASE_4Monoclonal Antibody1 trial
Active Trials
NCT01904279Completed52Est. May 2016
NCT01734382Completed35Est. Oct 2019
Genentech
GenentechCA - Oceanside
1 program
Biological DMARDsN/A
Parexel
ParexelMA - Boston
1 program
GivinostatN/ASmall Molecule1 trial
Active Trials
NCT01557452Terminated1Est. Jan 2014
Sandoz
SandozAustria - Kundl
1 program
SecukinumabN/AMonoclonal Antibody
Alliance Pharmaceuticals
1 program
Teens Taking ChargeN/A1 trial
Active Trials
NCT01011179Completed46Est. Jun 2009
Regeneron
RegeneronTARRYTOWN, NY
1 program
SarilumabPHASE_2Monoclonal Antibody

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
RocheTocilizumab
PfizerCP-690,550
AbbVieAdalimumab
PfizerGenotropin
PfizerTofacitinib
UNION therapeuticsGenakumab
RocheTocilizumab
AstraZenecanaproxen
ParexelGivinostat
Alliance PharmaceuticalsTeens Taking Charge
AbbVieadalimumab

Clinical Trials (11)

Total enrollment: 1,660 patients across 11 trials

NCT01734382RocheTocilizumab

A Study of Decreased Dose Frequency in Participants With Systemic Juvenile Arthritis Who Experience Laboratory Abnormalities During Treatment With RoActemra/Actemra (Tocilizumab)

Start: Jun 2013Est. completion: Oct 201935 patients
Phase 4Completed
NCT02592434PfizerCP-690,550

Efficacy Study Of Tofacitinib In Pediatric JIA Population

Start: Jun 2016Est. completion: May 2019225 patients
Phase 3Completed
NCT00775437AbbVieAdalimumab

Active Juvenile Idiopathic Arthritis (JIA) Compassionate Use

Start: Mar 2009Est. completion: Mar 201332 patients
Phase 3Completed
NCT00420251PfizerGenotropin

Efficacy and Safety of Growth Hormone Treatment in Juvenile Idiopathic Arthritis

Start: Mar 1996Est. completion: Jul 200650 patients
Phase 3Completed
NCT01500551PfizerTofacitinib

Long-Term Safety Study Of Tofacitinib In Patients With Juvenile Idiopathic Arthritis

Start: Mar 2013Est. completion: Feb 2025302 patients
Phase 2/3Completed
NCT04337437UNION therapeuticsGenakumab

Clinical Study of Genakumab for Injection in Chinese Healthy Volunteers

Start: Apr 2019Est. completion: Sep 202040 patients
Phase 1Unknown
NCT01904279RocheTocilizumab

A Study of Subcutaneously (SC) Administered Tocilizumab (TCZ) in Participants With Polyarticular-Course Juvenile Idiopathic Arthritis (pJIA)

Start: Jul 2013Est. completion: May 201652 patients
Phase 1Completed
NCT01358383AstraZenecanaproxen

Assessment of Pharmacokinetics of a Single Oral Dose of VIMOVO in Healthy Adult Volunteers

Start: May 2011Est. completion: Jun 201128 patients
Phase 1Completed
NCT01557452ParexelGivinostat

Open-Label Extension of the Dose Finding Study (DSC/08/2357/36) in Patients With Poly Juvenile Idiopathic Arthritis

Start: Dec 2011Est. completion: Jan 20141 patients
N/ATerminated
NCT01011179Alliance PharmaceuticalsTeens Taking Charge

Internet Self-Management Program With Telephone Support for Adolescents With Arthritis

Start: Nov 2008Est. completion: Jun 200946 patients
N/ACompleted
NCT00783510AbbVieadalimumab

Juvenile Idiopathic Arthritis (JIA) Registry

Start: Jul 2008Est. completion: Feb 2024849 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

5 late-stage (Phase 3) programs, potential near-term approvals
Monoclonal Antibody is the dominant modality (64% of programs)
16 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.